Drug
Tenofovir alafenamide clinical trials
Also written Vemlidy, TAF and GS-7340.
Keep track of what changes. Save the tenofovir alafenamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
136 studies that test it; most in 2021 (19)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 15 |
| 2016 | 10 |
| 2017 | 7 |
| 2018 | 10 |
| 2019 | 15 |
| 2020 | 14 |
| 2021 | 19 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 6 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 62 · Other 74
Gilead Sciences (49) · Third Affiliated Hospital, Sun Yat-Sen University (6) · Janssen Sciences Ireland UC (3) · Taichung Veterans General Hospital (2) · National Taiwan University Hospital (2) · Janssen Research & Development, LLC (2) · The Third Affiliated Hospital of Guangzhou Medical University (2) · Taipei Veterans General Hospital, Taiwan (2)
Often tested with
Tested in the same studies.
Emtricitabine (70) · Bictegravir (37) · Cobicistat (27) · Elvitegravir (19) · Darunavir (13) · Dolutegravir (7) · Lenacapavir (6) · Emtricitabine tenofovir alafenamide (5)
Studies
Open first, then newest update. How each study uses tenofovir alafenamide is read from its arms, and is right about nine times in ten.
Testing it · 136
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAF
- TAF vs TDF During the PregancyEnrolling by invitationPhase 4The Third Affiliated Hospital of Guangzhou Medical UniversityNCT07542951Written as TAF
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05652478Written as Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Tenofovir alafenamide (TAF)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine
- TAF in Early/Middle Pregnancy With CHBEnrolling by invitationPhase 4The Third Affiliated Hospital of Guangzhou Medical UniversityNCT07668934Written as TAF
- Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis BRecruitingPhase 4Taichung Veterans General HospitalNCT03933384Written as Tenofovir alafenamide
- Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy VolunteersRecruitingPhase 1Johns Hopkins UniversityNCT07349758Written as tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruitingPhase 4The Task Force for Global HealthNCT07258251Written as Tenofovir Alafenamide (TAF)
- Study of Tenofovir Alafenamide in HBV-Infected Pregnant WomenRecruitingPhase 4First People's Hospital of HangzhouNCT05853718Written as Tenofovir Alafenamide Tablets
- Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral LoadsRecruitingNot applicableGuangzhou 8th People's HospitalNCT06947356Written as TAF group
- To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant PatientsNot yet recruitingPhase 2Jongman KimNCT06589518Written as Tenofovir Alafenamide Citrate
- Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLFRecruitingNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT03920618Written as Tenofovir Alafenamide
- The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06375304Written as B/F/TAF
- Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.RecruitingNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT04231565Written as Tenofovir alafenamide Fumarate
- Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral TreatmentNot yet recruitingPhase 4Yonsei UniversityNCT06221657Written as Vemlidy
- TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.RecruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT05195450Written as Tenofovir alafenamide fumarate
See all 136 studies that test tenofovir alafenamide →
Given in every arm · 29 — tenofovir alafenamide is usual care beside what is tested
- Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponseNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07797231Written as Tenofovir Alafenamide Fumarate Tablets
- Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionNot yet recruitingEarly Phase 1Ningbo No.2 HospitalNCT07553767Written as TAF
- A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-InfectionNot yet recruitingPhase 2National Taiwan University HospitalNCT05467553Written as Tenofovir Alafenamide
- A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus InfectionCompletedPhase 2Huahui HealthNCT05861674Written as TAF
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult ParticipantsCompletedPhase 1Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06278389Written as Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
- A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D VirusCompletedPhase 2Janssen Research & Development, LLCNCT04535544Written as Tenofovir alafenamide (TAF)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedPhase 2/3Gilead SciencesNCT01854775Written as E/C/F/TAF
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)CompletedPhase 2Gilead SciencesNCT04891770Written as Tenofovir Alafenamide
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenCompletedPhase 2/3Gilead SciencesNCT02285114Written as F/TAF
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04439539Written as Tenofovir alafenamide
- A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 1Janssen Research & Development, LLCNCT05123599Written as TAF
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04585789Written as Tenofovir alafenamide (TAF)
- Study of Novel Antiretrovirals in Participants With HIV-1CompletedPhase 1Gilead SciencesNCT05585307Written as B/F/TAF
- An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B ParticipantsCompletedPhase 2Janssen Research & Development, LLCNCT05275023Written as Tenofovir Alafenamide
- A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT04129554Written as Tenofovir alafenamide (TAF)
- A Single and Multiple Ascending Dose Study of JNJ-64457744TerminatedPhase 1Janssen Research & Development, LLCNCT05423106Written as Tenofovir Alafenamide (TAF)
- A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis BActive, not recruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06150014Written as Tenofovir alafenamide fumarate tablet
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B PatientsCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT05244057Written as Tenofovir Alafenamide Tablets
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04667104Written as Tenofovir alafenamide (TAF)
- Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid TumorsTerminatedPhase 3SWOG Cancer Research NetworkNCT03887702Written as Tenofovir Alafenamide
Showing 20 of 29.
As the comparator · 19 — what is tested is compared with tenofovir alafenamide
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsRecruitingPhase 2Gilead SciencesNCT07841990Written as B/F/TAF
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as BIC/FTC/TAF
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as DTG+FTC/TAF
- A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis BRecruitingPhase 3Zhigang RenNCT07307586Written as TAF
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityRecruitingPhase 3José Antonio Mata MarínNCT07075146Written as BIC/FTC/TAF
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07031063Written as Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingPhase 3ViiV HealthcareNCT05979311Written as Tenofovir alafenamide
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as BIC/FTC/TAF
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as BIC/FTC/TAF
- Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingPhase 2/3Gilead SciencesNCT06544733Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedPhase 2/3Gilead SciencesNCT06613685Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as BIC/FTC/TAF
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedPhase 2Merck Sharp & Dohme LLCNCT04564547Written as BIC/FTC/TAF
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as BIC/FTC/TAF
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06891066Written as BIC/FTC/TAF
- Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04636437Written as Tenofovir alafenamide/emtricitabine
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainCompletedPhase 4Janssen Scientific Affairs, LLCNCT04442737Written as TAF/FTC FDC
- Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis BCompletedPhase 1Nucorion Pharmaceuticals, Inc.NCT04629976Written as Tenofovir Alafenamide 25 mg
- Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty LiverStatus unknownPhase 4IlDong Pharmaceutical Co LtdNCT03604016Written as Tenofovir Alafenamide
Codes
What other systems call tenofovir alafenamide · ClinicalTrials.gg INT004405
- MeSH (NLM) C442442tenofovir alafenamideConfirmed NLM, Wikidata
- UNII (FDA) EL9943AG5JTENOFOVIR ALAFENAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1721603Confirmed FDA, Wikidata
- Wikidata Q22075912tenofovir alafenamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148276Tenofovir AlafenamideOne source FDA
- DrugBank DB09299One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C442442 | tenofovir alafenamide | Confirmed NLM, Wikidata |
| UNII (FDA) | EL9943AG5J | TENOFOVIR ALAFENAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721603 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075912 | tenofovir alafenamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148276 | Tenofovir Alafenamide | One source FDA |
| DrugBank | DB09299 | — | One source Wikidata |
Also registered as tenofovir alafenamide fumarate (UNII FWF6Q91TZO · RxNorm 1721604).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.